David Hopkins, DO
Family Medicine · Guthrie, OKNPI 1265626352
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $438 and has fallen 93.1% since, to $30 in 2025.
Across 52 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$105
- Novo Nordisk$86
- Astellas Pharma US Inc$75
- GSK$69
- Pfizer$66
- Shire North American Group Inc$56
- plus $307 from 14 others
What the payments were for
- Food & beverage$763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $105 |
| Novo Nordisk | 6 | $86 |
| Astellas Pharma US Inc | 5 | $75 |
| GSK | 4 | $69 |
| Pfizer | 5 | $66 |
| Shire North American Group Inc | 4 | $56 |
| Lilly USA, LLC | 2 | $39 |
| AstraZeneca | 3 | $39 |
| Johnson & Johnson | 3 | $36 |
| Amarin Pharma, Inc. | 2 | $28 |
| Novartis | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Abbott | 1 | $17 |
| Strongbridge US Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$763 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $678 |
| Methylprednisolone | 35 | $295 |
| Doxycycline Hyclate | 35 | $279 |
| Cephalexin | 24 | $175 |
| Ondansetron OdtOndansetron | 13 | $96 |
| Lisinopril | 11 | $80 |
| Amoxicillin | 29 | $78 |
| Azithromycin | 27 | $61 |
| Montelukast Sodium | 11 | $56 |
| Cyclobenzaprine Hcl | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Guthrie
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.